Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Absolutely right
IMUN stock price is relative as long as CBLI SP keep increasing
At March 31, 2021, the Company has an equity interest of 13.3% in Cytocom.
note conversion
During the first quarter of 2021, the Company issued 5,402 common shares, at a price of $10.40 per share, upon the conversion of $53,000 in promissory notes and $3,480 in accrued interest. The Company did not issue any in new promissory notes during the three months ended March 31, 2021.
Absolutely!
Take look some other companies like AABB 400M MCAP, completely a scam company, $RGBP 63M MCAP
1Q2021 huge financial improvements compared to other quarters.
March 31, 2021 March 31, 2020
Income $790,407 (792,873)
Cash 110,658. 6,153
I hope so too!
News coming!
$imund current market cap 3.8M and the equity stake on cyto 13M plus royalties on total revenue after the merger.
Everything is spelled out in s4 report filed by CBLI. Cyto will receive 26M shares and IMUN owns 9.76% of 26M. IMUN will receive 2.5M shares plus 1-3% royalties for total revenue.
Insane market cap 2.4M and the equity stake that IMUN owned of cyto is currently 5M,
Raising money it will not be issued. Specially when the company has Russia billionaire majority shareholder
CBLI nice jump today
Reverse merger are picking up! IMUN is perfect candidate for reverse merger
Yes correct! Only preferred stock are protected from RS, no toxic financing currently on books.
Promissory notes aggregating $533,855 were issued in 2018, of which $210,000 is to a related party. The notes accrue interest at 2% and mature between January 2019 and November 2019. These notes include warrants between 200 and 39,500 shares with an exercise price of $5 to $40. In connection with an August 16, 2020 agreement with Cytocom, $210,000 of the notes were assumed by Cytocom. These notes are in default. $323,855
The exercised price of convertible debt into shares are $5-$40 per share
No they are not protected.
“The short sellers would have a field day with this one” 482K share outstanding and majority of these shares owned by Robert daily 21M shares, noreen 62M, Iliad Research & Trading, L.P. 45M, plus individual investors over 100M
“They do reverse splits when there are no more shares left to issue, thereby enabling them to start the fund raising and dilution all over again.” Don’t make any sense
Authorized Shares 750M -482M = 268M shares available before. They management could have diluted before the RS
Immune therapeutics
I don’t know but my account shown the correct name
Which brokerage company do you have
he will probably use both companies as collateral to raise money.
It’s amazing focus who don’t own shares are in attack. Keep posting garbage because I’m not selling.
Lol “insider trading so NO” he never disclosed what the plan was. I’m done going back and forth with you
It’s I’m fine with that!
Lol I’m not selling
It’s ridiculous to the low and the company is backed by the same investor that owns sharers into cyto. Patience is very important
Interesting blurb from S-4 filed by CBLI “As of December 31, 2020, the directors and executive officers of Cleveland BioLabs, together with Mr. Davidovich, owned or controlled approximately 48.9% of the outstanding shares of Cleveland BioLabs common stock entitled to vote at the Cleveland BioLabs special meeting.”
Mr. Davidovich is billionaire and closed friend to Roman Abramovich's which is worth 8-10B
As of 05/11/2021 Outstanding shares 482,345 and $6.5M Market cap
It Will takes 5-7 business days for transfer agent to release the shares into brokerage companies
$AREVF “AREV Nanotec Board of Directors Welcomes Kevin Phelps Kevin J. Phelps to its Board of Directors. Mr. Phelps has a long history in the biotechnology and drug discovery industries, currently serving as the CEO of Immune Therapeutics, Inc”
All options are on the table eg reverse merger, acquired new assets.
No toxic financing currently as options. He is looking to raise funds through putting cyto assets as collateral.
Very excited about the future of company after spoken with Kevin
Probably transfer agent hasn’t released the shares to brokerage companies that why you can’t see it.
Okay nuts
The ceo is experienced and hopefully he delivers on his promise “ creating shareholders value”
Okay! A lot of things have changed since 2 years ago. IMUN owns 9.76% cyto roughly 2.5M shares after the merger.
Dude you are not answering the question. Kevin email April 2021 “We hope to make some announcements soon regarding the future of the Company. We will be filing out own 10K Auunal Report tomorrow. It will be available on our website”